Gene Therapy · us
Gene Therapy for Hereditary Hearing Loss Moves Toward Younger Ages: SKY-GJB2 Recommended for Children Under Two
Safety data from four older children have led to a review recommendation to expand the SONIX trial to younger ages. Whether earlier intervention can improve hearing and language development awaits human efficacy data.
For children born with hereditary hearing loss, the timing of treatment affects not only whether they can hear sounds but also their subsequent ability to understand speech and learn to communicate. Skylark Bio announced on November 18 that an independent data safety monitoring board had unanimously recommended advancing the early human trial of SKY-GJB2, its gene therapy for GJB2-related hearing loss, to children aged 9 months to under 2 years.
The recommendation followed a review of safety data from the first four participants in the Phase 1/2 SONIX trial, who were aged 2 to 7 years. The board concluded that the study could proceed to its second cohort and recruit younger children. However, this safety review judgment supports the trial's continued progression; it does not mean the therapy has been shown to improve hearing, nor does it constitute marketing approval.
The GJB2 gene produces connexin 26, which participates in the network of gap junctions between inner ear cells and helps maintain the environment required for normal cochlear function. Genetic variants that disrupt this mechanism can cause hearing loss. SKY-GJB2 is designed to deliver a functional copy of the GJB2 gene into cochlear supporting cells in an attempt to repair the affected network at the cellular level.
SONIX is a multicenter, open-label study evaluating this therapy in humans for the first time. It assesses safety, tolerability, and preliminary changes in hearing following a single injection into one cochlea. This approach aims to address the genetic root of hearing loss. Existing hearing aids and cochlear implants help provide access to sound information in different ways but do not correct the GJB2 gene abnormality.
Lowering the recruitment age to under two brings the study into an important period of auditory and language development. Hearing Health & Technology Matters noted that researchers hope to learn whether addressing the disease-causing mechanism during this period can produce meaningful improvements in hearing. However, whether earlier dosing is more effective, and whether changes in hearing can translate into benefits for language development, remain unanswered.
The announcement did not provide specific hearing test results for the four children or detail adverse events and follow-up duration, so it cannot establish the magnitude of improvement or long-term risks. The initial sample of just four participants also limits conclusions about safety. Given the open-label design, subsequent results will need to be interpreted alongside the assessment methods and length of follow-up.
According to the company's timeline, the study is expected to obtain preliminary clinical data by the end of 2026 and report its first results in 2027. The current development marks the next step toward allowing younger children to participate in the research. Whether the therapy can produce sustained, practically meaningful changes in hearing remains to be demonstrated by subsequent data.